Screener
Ocugen, Inc.
OCGNOcugen is a late-stage biotechnology company focused on developing first-in-class modifier gene therapies to treat inherited retinal diseases and blindness.
$338.57M-17.9%
Earnings
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$1.1M
EPS estimate-$0.06
Competitors
By market cap
By revenue growth
Profile
Ocugen is a late-stage biotechnology company focused on developing first-in-class modifier gene therapies to treat inherited retinal diseases and blindness. The company utilizes a novel gene-agnostic platform designed to address multiple genetic mutations with a single therapy, alongside regenerative cell therapy and inhaled mucosal vaccine platforms.
Competitive position
A pioneer in gene-agnostic modifier therapies for retinal diseases with multiple programs in late-stage clinical trials.
GeographiesUnited States, European Union
Customer segmentsPatients, Specialized medical centers
Business modelR&D intensive, Biopharmaceutical development
SuppliersSpecialized GMP manufacturing facilities, Clinical research organizations, AAV5 delivery technology providers
CustomersOphthalmologists, Specialty pharmacies, Hospitals
CountryUnited States of America
Listed2014
Employees84.0
CEOShankar Musunuri
SectorHealthcare
IndustryBiotechnology
Websiteocugen.com
FilingsSEC EDGAR
FAQ
- What is Ocugen, Inc.'s market cap?
- Ocugen, Inc. (OCGN) has a market capitalization of $338.6M and trades on NASDAQ.
- Who are Ocugen, Inc.'s competitors?
- Ocugen, Inc.'s key competitors include Opus Genetics, Inc. Common Stock, Lineage Cell Therapeutics, Inc., REGENXBIO Inc., and others. These companies compete in similar markets and product categories.
- Who does Ocugen, Inc. partner with?
- Ocugen, Inc.'s notable partners include National Institute of Allergy and Infectious Diseases, National Institutes of Health, Regeneron Pharmaceuticals, and others.
- What subsidiaries does Ocugen, Inc. have?
- Ocugen, Inc.'s subsidiaries include OrthoCellix, Inc..
- Where is Ocugen, Inc. headquartered?
- Ocugen, Inc. is headquartered in United States of America and employs approximately 84 people. It has been publicly traded since 2014.